{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:07:26Z","timestamp":1774566446685,"version":"3.50.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sintilimab is an effective PD-1 immune checkpoint inhibitor (ICI) for advanced non-small cell lung cancer (NSCLC). However, it can cause severe immune-related adverse events (irAEs) such as toxic epidermal necrolysis (TEN), a rare hypersensitivity reaction with significant mortality. Reports of Sintilimab-induced TEN are exceedingly rare, making its recognition and management crucial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>A 60-year-old female with advanced NSCLC developed TEN 3\u00a0days after her second dose of Sintilimab. The condition progressed rapidly, with epidermal detachment affecting 85% of her body surface area (BSA). Immediate interventions, including high-dose corticosteroids, intravenous immunoglobulin, meticulous wound care, and infection control, led to gradual recovery. After 39 days of intensive care, the patient was discharged with complete healing of skin lesions and no significant complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This report highlights the potential for Sintilimab to induce life-threatening TEN, emphasizing the need for vigilant monitoring and prompt intervention during ICIs therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1610305","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T08:29:26Z","timestamp":1769675366000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Toxic epidermal necrolysis induced by sintilimab in a patient with advanced lung squamous cell carcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Jiaxing","family":"Wu","sequence":"first","affiliation":[{"name":"School of Medicine, Nankai University","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingjun","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Sino Singapore Cancer Centre","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nursing, Sino Singapore Cancer Centre","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingqun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sino Singapore Cancer Centre","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ailing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sino Singapore Cancer Centre","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanli","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sino Singapore Cancer Centre","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/15569527.2022.2034842","article-title":"Adverse cutaneous toxicities by PD-1\/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance","volume":"41","author":"Bhardwaj","year":"2022","journal-title":"Cutan. Ocular Toxicol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3390\/medicina57090895","article-title":"Stevens\u2013johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management","volume":"57","author":"Frantz","year":"2021","journal-title":"Medicina"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE \u2013 version 5.0) to evaluate the severity of adverse events of anticancer therapies","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"B4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jaci.2022.12.005","article-title":"Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions","volume":"151","author":"Gibson","year":"2023","journal-title":"J. Allergy Clinical Immunology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann. Oncology Official Journal Eur. Soc. Med. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.5603\/AIT.2015.0037","article-title":"Toxic epidermal necrolysis","volume":"47","author":"Hinc-Kasprzyk","year":"2015","journal-title":"Anaesthesiol. Intensive Therapy"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5061","DOI":"10.2147\/JIR.S427336","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome following sintilimab administration in a non-small cell lung cancer patient: a case report","volume":"16","author":"Jiang","year":"2023","journal-title":"J. Inflamm. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"989966","DOI":"10.3389\/fimmu.2022.989966","article-title":"Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: a case report","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"912168","DOI":"10.3389\/fonc.2023.912168","article-title":"Case report: sintilimab-induced Stevens-Johnson syndrome in a patient with advanced lung adenocarcinoma","volume":"13","author":"Li","year":"2023","journal-title":"Front. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.5021\/ad.21.072","article-title":"Toxic epidermal necrolysis induced by sintilimab: a case report","volume":"35","author":"Lye","year":"2023","journal-title":"Ann. Dermatology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2021.06.010","article-title":"Ocular manifestations of anti-neoplastic immune checkpoint inhibitor-associated stevens-johnson syndrome\/toxic epidermal necrolysis in cancer patients","author":"Ma","year":"2021","journal-title":"Ocular Surface"},{"key":"B11","doi-asserted-by":"publisher","first-page":"7591","DOI":"10.2147\/JIR.S491791","article-title":"Clinical features of Stevens-Johnson syndrome and toxic epidermal necrolysis induced by immune checkpoint inhibitor versus non-immune checkpoint inhibitor drugs in China: a cross-sectional study and literature review","volume":"17","author":"Qin","year":"2024","journal-title":"J. Inflamm. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/ACI.0000000000000914","article-title":"New insights into the diagnosis and management of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"23","author":"Saito","year":"2023","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: Comparison with case\u2013control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin. Pharmacol. and Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/1346-8138.17039","article-title":"Immune checkpoint inhibitor\u2010induced epidermal necrolysis: a narrative review evaluating demographics, clinical features, and culprit medications","volume":"51","author":"Satoh","year":"2023","journal-title":"J. Dermatology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40257-024-00889-6","article-title":"Update on Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: diagnosis and management","volume":"25","author":"Shah","year":"2024","journal-title":"Am. J. Clin. Dermatology"},{"key":"B18","first-page":"7","article-title":"Toxic epidermal necrolysis: a review of past and present therapeutic approaches","volume":"27","author":"Singh","year":"2022","journal-title":"Skin. Therapy Letter"},{"key":"B19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/pde.13172","article-title":"Score of toxic epidermal necrosis predicts the outcomes of pediatric epidermal necrolysis","volume":"34","author":"Sorrell","year":"2017","journal-title":"Pediatr. Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1111\/1346-8138.15490","article-title":"Accuracy of SCORTEN and ABCD\u201010 to predict mortality and the influence of renal function in stevens\u2013johnson syndrome\/toxic epidermal necrolysis","volume":"47","author":"Torres-Navarro","year":"2020","journal-title":"J. Dermatology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16137","article-title":"Accuracy of SCORTEN to predict the prognosis of stevens\u2010johnson syndrome\/toxic epidermal necrolysis: a systematic review and meta\u2010analysis","volume":"34","author":"Torres-Navarro","year":"2019","journal-title":"J. Eur. Acad. Dermatology Venereol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1080\/19420862.2019.1654303","article-title":"Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit","volume":"11","author":"Wang","year":"2019","journal-title":"mAbs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40364-022-00363-7","article-title":"Sintilimab for the treatment of non-small cell lung cancer","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomark. Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2217\/imt-2023-0081","article-title":"Lichenoid dermatitis following PD-1 inhibitor-induced toxic epidermal necrolysis: a case report and literature review","volume":"15","author":"Zhang","year":"2023","journal-title":"Immunotherapy"},{"key":"B25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3779\/j.issn.1009-3419.2021.101.13","article-title":"Chinese experts consensus on immune checkpoint inhibitors for non-small cell lung cancer (2020 version). Zhongguo fei ai za zhi= Chinese","volume":"24","author":"Zhou","year":"2021","journal-title":"J. Lung Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1414136","DOI":"10.3389\/fimmu.2024.1414136","article-title":"Stevens-johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1610305\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T08:29:32Z","timestamp":1769675372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1610305\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":26,"alternative-id":["10.3389\/fphar.2026.1610305"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1610305","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"article-number":"1610305"}}